Details for Patent: 8,933,030
✉ Email this page to a colleague
Which drugs does patent 8,933,030 protect, and when does it expire?
Patent 8,933,030 protects LINZESS and is included in one NDA.
This patent has seventeen patent family members in thirteen countries.
Summary for Patent: 8,933,030
| Title: | Treatments for gastrointestinal disorders |
| Abstract: | The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor. |
| Inventor(s): | Fretzen; Angelika (Somerville, MA), Zhao; Hong (Lexington, MA), Kessler; Marco (Danvers, MA) |
| Assignee: | Ironwwod Pharmaceuticals, Inc. (Cambridge, MA) |
| Application Number: | 13/579,685 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,933,030 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
Drugs Protected by US Patent 8,933,030
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | LINZESS | linaclotide | CAPSULE;ORAL | 202811-003 | Jan 25, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS. | ⤷ Sign Up | |||
| Abbvie | LINZESS | linaclotide | CAPSULE;ORAL | 202811-003 | Jan 25, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF FUNCTIONAL CONSTIPATION IN PEDIATRIC PATIENTS 6 TO 17 YEARS OF AGE | ⤷ Sign Up | |||
| Abbvie | LINZESS | linaclotide | CAPSULE;ORAL | 202811-001 | Aug 30, 2012 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Abbvie | LINZESS | linaclotide | CAPSULE;ORAL | 202811-002 | Aug 30, 2012 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,933,030
| PCT Information | |||
| PCT Filed | February 17, 2011 | PCT Application Number: | PCT/US2011/025274 |
| PCT Publication Date: | August 25, 2011 | PCT Publication Number: | WO2011/103311 |
International Family Members for US Patent 8,933,030
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011218009 | ⤷ Sign Up | |||
| Australia | 2017200588 | ⤷ Sign Up | |||
| Australia | 2019202052 | ⤷ Sign Up | |||
| Canada | 2790213 | ⤷ Sign Up | |||
| China | 102869677 | ⤷ Sign Up | |||
| China | 116825726 | ⤷ Sign Up | |||
| Denmark | 2536742 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
